Download a copy of our advance programme for a glimpse of what’s in store for the CBD Global Summit 2020 including the line-up of expert speakers, the agenda at-a-glance, the key themes & topics that will be covered and more.





Hemp and CBD have caught the public’s imagination as ingredients offering a host of health benefits. The global CBD market is accelerating at a tremendous pace as innovative entrepreneurs introduce a plethora of ways to consume CBD.

A consumer-centric approach to innovation will be crucial to support future growth in CBD. What is motivating the CBD consumer? What do shoppers want from the category? And how can innovators meet these needs?


An impending explosion of innovative product development leveraging CBD is on the horizon.

What approaches are top retailers taking to CBD ranging? How are innovative new brands across a variety of sectors – from cosmetics to grocery – driving growth in the area? We’ll be taking a category-based approach to profile the most exciting disruptors delivering products with a unique positioning around CBD.


The biggest headache in 2020 for manufacturers working in CBD will be navigating a challenging regulatory environment. Unlike hemp – which is legal in the EU and other markets – the legal status of products containing CBD is far from clear. In the US, the Food and Drug Administration states that ingestible CBD is not permitted. Nevertheless, products are widely available and the new Farm Bill would appear to make all hemp products legal.

The situation in the European Union is no less confusing. CBD falls under the Novel Food regulation, meaning it requires pre-market authorisation. But each EU member state can take an alternative position – which allows for CBD food products to be sold. In Brexit Britain, for example, the government has so far adopted a passive approach and allowed CBD products to on the market. But nobody knows what the position will be after Brexit.

CBD is an ingredient caught in a regulatory grey area. To succeed in the sector, manufacturers must consider the risks and opportunities presented by this difficult landscape.


CBD is a derivate of the cannabis plant. Unlike THC, which is responsible for cannabis’s ‘high’, CBD is not psychoactive.

The cannabinoid has been linked to a number of positive health outcomes. In medical uses, robust evidence points to CBD’s effectiveness in treating some symptoms of childhood epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS). In the FMCG space, CBD is commonly associated with reducing anxiety, insomnia and different types of chronic pain.

The broad applications of CBD have resulted in it being hailed as something of a ‘wonder drug’. But for all the hype, much of the research into CBD’s impact on health is still in its early stages.

It is vital that claims linked to CBD products remain credible if the category is to maintain consumer trust. We look at the science behind CBD to ask exactly what claims stack up.


Throughout the FMCG space, consumers are demanding transparency. But booming demand for CBD products presents manufacturers with challenges around quality of supply. The need to deliver traceable and safe products is paramount. A significant health or safety scare has the potential to stop the high-growth but fledgling CBD sector in its tracks.

We will hear top tips from industry experts about how CBD manufacturers can shore up their supply chains and guarantee high quality finished products.